Abstract:Alzheimer's disease (AD) is the most common dementia-causing disorder in the elderly; it may be related to multiple risk factors, and is characterized pathologically by cerebral hypometabolism, paravascular β-amyloid peptide (Aβ) plaques, neuritic dystrophy, and intra-neuronal aggregation of phosphorylated tau. To explore potential pathogenic links among some of these lesions, we examined β-secretase-1 (BACE1) alterations relative to Aβ deposition, neuritic pathology and vascular organization in aged monkey and AD human cerebral cortex. Western blot analyses detected increased levels of BACE1 protein and β-site-cleavage amyloid precursor protein C-terminal fragments in plaque-bearing human and monkey cortex relative to controls. In immunohistochemistry, locally elevated BACE1 immunoreactivity (IR) occurred in AD but not in control human cortex, with a trend for increased overall density among cases with greater plaque pathology. In double-labeling preparations, BACE1 IR colocalized with immunolabeling for Aβ but not for phosphorylated tau. In perfusion-fixed monkey cortex, locally increased BACE1 IR co-existed with intra-axonal and extracellular Aβ IR among virtually all neuritic plaques, ranging from primitive to typical cored forms. This BACE1 labeling localized to swollen/sprouting axon terminals that might co-express one or another neuronal phenotype markers (GABAergic, glutamatergic, cholinergic, or catecholaminergic). Importantly, these BACE1-labeled dystrophic axons resided near to or in direct contact with blood vessels. These findings suggest that plaque formation in AD or normal aged primates relates to a multisystem axonal pathogenesis that occurs in partnership with a potential vascular or metabolic deficit. The data provide a mechanistic explanation for why senile plaques are present preferentially near the cerebral vasculature.

Brains of rhesus monkeys display Aβ deposits and glial pathology while lacking Aβ dimers and other Alzheimer's pathologies.

Distribution, progression and chemical composition of cortical amyloid-β deposits in aged rhesus monkeys: similarities to the human

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer’s disease in nonhuman primates

Rhesus monkeys as a translational model for late‐onset Alzheimer's disease

Age-associated changes in amyloid-β and formaldehyde concentrations in cerebrospinal fluid of rhesus monkeys

Pathological Markers of Alzheimer's Disease and Related Dementia in the Rhesus Macaque Amygdala

Senile plaques and phosphorylated tau deposition in a super-aged rhesus monkey (Macaca mulatta)

β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation

Β‐secretase‐1 Elevation in Aged Monkey and Alzheimer’s Disease Human Cerebral Cortex Occurs Around the Vasculature in Partnership with Multisystem Axon Terminal Pathogenesis and Β‐amyloid Accumulation

Human Alzheimer's Disease ATN/ABC Staging Applied to Aging Rhesus Macaque Brains: Association With Cognition and MRI‐Based Regional Gray Matter Volume

Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease

Resting-state Global Brain Activity Affects Early Β-Amyloid Accumulation in Default Mode Network.

Amyloid-β Pathology Is the Common Nominator Proteinopathy of the Primate Brain Aging

A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis

A Non-Human Primate Model with Alzheimer's Disease-Like Pathology Induced by Hippocampal Overexpression of Human Tau

Alzheimer's Disease-Like Pathologies and Cognitive Impairments Induced by Formaldehyde in Non-Human Primates

Towards developing a rhesus monkey model of early Alzheimer's disease focusing on women's health

Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition

The amyloid hypothesis of Alzheimer's disease at 25 years

Intracerebral inoculation of healthy non-transgenic rats with a single aliquot of oligomeric amyloid-β (1-42) profoundly and progressively alters brain function throughout life